Inosine

Inosine

SCHEMBL18653532

OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 4/20 0.75
ADORA3 P0DMS8 2/20 0.75
MAPK1 P28482 2/20 0.75
ADORA1 P30542 2/20 0.75
SMN1; SMN2 Q16637 2/20 0.75
DPP4 P27487 1/20 0.75
MEN1 O00255 1/20 0.75
SLC28A1 O00337 1/20 0.75
MAP3K7 O43318 1/20 0.75
SLC28A2 O43868 1/20 0.75
GAPDH P04406 1/20 0.75
ADORA2A P29274 1/20 0.75
ADORA2B P29275 1/20 0.75
STAT6 P42226 1/20 0.75
PI4KA P42356 1/20 0.75
KMT2A Q03164 1/20 0.75
PI4K2B Q8TCG2 1/20 0.75
DOT1L Q8TEK3 1/20 0.75
PI4K2A Q9BTU6 1/20 0.75
SLC28A3 Q9HAS3 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Inosine SCHEMBL12763613 1.00 SLC29A1 (0.75) SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2
Inosine SCHEMBL2229394 1.00 SLC29A1 (0.75) SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2
Inosine SCHEMBL2046912 1.00 SLC29A1 (0.75) SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2
Inosine SCHEMBL20138477 1.00 SLC29A1 (0.75) SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2
Inosine SCHEMBL15804 1.00 SLC29A1 (0.75) SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2
Inosine SCHEMBL4110068 1.00 SLC29A1 (0.75) SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2
Inosine SCHEMBL6748954 1.00 SLC29A1 (0.75) SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2
Inosine SCHEMBL298755 1.00 SLC29A1 (0.75) SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2
Inosine SCHEMBL330178 1.00 SLC29A1 (0.75) SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2
Inosine SCHEMBL29436140 1.00 SLC29A1 (0.75) SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11078227-B2 5′-cyclo-phosphonate modified nucleotides Arrowhead Pharmaceuticals, Inc. (US) 2021-08-03 US claimed
US-9605261-B2 RNA synthesis—phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end CHEMGENES CORPORATION (US) 2017-03-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11078227-B2 5′-cyclo-phosphonate modified nucleotides ENPP1, DCTPP1, PNKP SLC29A1 501/4885ADORA3 1379/4885MAPK1 3478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.